Ultime notizie per Lantern Pharma (NASDAQ:LTRN) Azioni

Lantern Pharma

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Lantern Pharma Inc

General

LTRN

Lantern Pharma shares are trading higher after the company announced LP-184 received FDA fast-track designation status for Glioblastoma.

News

Lantern Pharma's LP-184 Receives FDA Fast-Track Designation In Glioblastoma

Biotech

Lantern Pharma Receives Three FDA Rare Pediatric Disease Designations For LP-184 In Malignant Rhabdoid Tumors, Rhabdomyosarcoma, And Hepatoblastoma, Bringing Total To Four RPDDs

<a href="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf" title="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf">https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf</a>

Analyst Ratings

Trading Ideas

Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation

WIIM

Lantern Pharma shares are trading lower. The company reported Q2 financial results.

Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.55) by 16.36 percent. This is a 4.55 percent decrease over losses of $(0.44) per share from the same period last year.

Earnings

Earnings Beats

Lantern Pharma Q2 2024 GAAP EPS $(0.46) Beats $(0.55) Estimate

Lantern Pharma Announces Significant Advancement In Preclinical Synergy Of LP-184 With Checkpoint Inhibitors; To Present Data At Immuno-Oncology Summit 2024

<ul>
<li>The Phase 2 HARMONIC&#x2122; study is designed for never smokers with lung adenocarcinoma with the objective to overcome driver mutation(s) – which are more common in never smokers – that lead to tyrosine kinase inhibitor (TKI) treatment resistance, and to enhance patient outcomes when LP-300 is used with the standard-of-care chemotherapy doublet.</li>
<li>In the Phase 2 lead-in cohort of 7 patients, 6 patients experienced clinical benefit from the combination of LP-300 and chemotherapy while 1 patient experienced progressive disease.</li>
<li>Of the 6 patients experiencing clinical benefit – 3 patients showed partial responses with an average tumor size reduction of 51% and 3 patients have stable disease with an average tumor size reduction of 13%.</li>
<li>The clinical benefit rate and disease control rate is 86% for this group with an objective response rate (ORR) of 43%.</li>
<li>A preliminary analysis of data in the safety lead-in part of the trial indicates no additional safety concerns with no observed dose limiting toxicities (DLTs) and no reported treatment-related serious adverse events (SAEs).</li>
<li>Encouraging preliminary efficacy results were observed regardless of prior tyrosine kinase inhibitor (TKI) treatment(s), demographics, and metastatic disease sites.</li>
<li>In the initial set of patients, those having low to intermediate TMB (tumor mutation burden) were found to be responsive to LP-300 + chemotherapy.</li>
<li>There are no currently approved therapies or targeted agents specifically approved for use in NSCLC among never-smokers, which is a growing global class of patients.</li>
</ul>
Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced positive, preliminary results from the initial patient group in the ongoing HARMONIC&#x2122; phase 2 clinical trial. HARMONIC&#x2122; is evaluating Lantern Pharma's investigational new drug candidate, LP-300, in combination with pemetrexed and carboplatin in never smokers1 with advanced non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with a tyrosine kinase inhibitor (TKI). LP-300 was advanced in part with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lanternpharma.com%2Fai-platform&amp;esheet=54104073&amp;newsitemid=20240805396240&amp;lan=en-US&amp;anchor=Lantern%26%238217%3Bs+AI+platform%2C+RADR%26%23174%3B&amp;index=1&amp;md5=32bb134540850a577eaa35f44e4c1a77">Lantern's AI platform, RADR&#xAE;</a>, to aid in the validation of mechanisms and uncover insights in targeted patient populations. RADR&#xAE; is Lantern's AI platform for cancer therapy discovery, development and rescue with over 100 billion data points and aiding in the development of both Lantern's portfolio and development initiatives with Lantern's collaborators.

Lantern Pharma Shares Clinical Update From Ongoing Phase 2 HARMONIC Clinical Trial For Never Smokers With Advanced NSCLC, Including An 86% Clinical Benefit Rate In The Initial Patient Cohort

Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagnostic for its drug candidate LP-184. The diagnostic is currently based on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FReal-time_polymerase_chain_reaction&amp;esheet=54092753&amp;newsitemid=20240710249401&amp;lan=en-US&amp;anchor=qRT-PCR&amp;index=1&amp;md5=9a1c9951081542f28089f718b6c729f7">qRT-PCR</a> (quantitative real-time polymerase chain reaction) technology and is focused on quantifying the amount of PTGR1 RNA in patient tumor samples to assess the potential for sensitivity to Lantern's drug candidate LP-184. The company plans to further develop and validate the assay for its use as a potential tool for patient selection in later stage clinical trials across a broad range of solid tumors that have shown sensitivity to LP-184.

Lantern Pharma Achieves Milestone Towards Development Of Molecular Diagnostic For Use In Oncology Clinical Trials For Patient Selection And Stratification With Drug Candidate LP-184;  Confirmed PTGR1 As A Key Biomarker That It Intends To Use To Optimize Patient Selection Based On Potential Tumor Sensitivity To The Drug Candidate LP-184

Lantern Estimates That LP-284 Can Have The Potential To Improve Outcomes For 40,000 To 80,000 Patients With Blood Cancers Annually, With A Global Annual Market Potential Of $4B

Lantern Pharma Announced That The Japan Patent Office Has Issued A Certificate Of Patent For Composition Of Matter Covering Drug Candidate LP-284

<h3>Gainers</h3>
<ul>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. </li>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) shares rose 13.5% to $13.7. The market value of their outstanding shares is at $484.7 million. As per the press release, Q1 earnings came out today. </li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) stock moved upwards by 12.19% to $0.92. The market value of their outstanding shares is at $162.6 million. The company's, Q1 earnings came out today. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) shares moved upwards by 7.77% to $1.94. The market value of their outstanding shares is at $60.1 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock moved upwards by 6.94% to $0.77. The market value of their outstanding shares is at $174.1 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock moved upwards by 6.43% to $6.48. The company's market cap stands at $69.7 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Augmedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUGX#NASDAQ">AUGX</a>) shares fell 33.8% to $1.55 during Monday's after-market session. The company's market cap stands at $75.8 million. The company's, Q1 earnings came out today. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock decreased by 19.91% to $3.3. The market value of their outstanding shares is at $162.9 million. As per the press release, Q1 earnings came out today. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 5.0% to $0.21. The market value of their outstanding shares is at $10.3 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock declined by 4.81% to $3.37. The company's market cap stands at $184.1 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) stock decreased by 4.71% to $1.62. The company's market cap stands at $47.5 million. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock declined by 4.08% to $4.0. The market value of their outstanding shares is at $103.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AKYA

AUGX

CLDI

ELEV

GOSS

HROW

MODD

NOTV

RMTI

VXRT

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) shares rose 14.3% to $7.04 during Friday's after-market session. The company's market cap stands at $75.7 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares moved upwards by 7.82% to $6.2. The market value of their outstanding shares is at $9.8 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) shares increased by 7.44% to $0.55. The market value of their outstanding shares is at $14.3 million. </li>
<li>Dominari Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>) stock moved upwards by 5.21% to $2.22. The company's market cap stands at $13.1 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock increased by 4.97% to $2.11. The market value of their outstanding shares is at $18.4 million. </li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) shares moved upwards by 4.96% to $0.74. The company's market cap stands at $130.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) shares decreased by 6.2% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $2.1 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) stock fell 5.3% to $9.84. The company's market cap stands at $372.5 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock decreased by 5.3% to $0.09. The company's market cap stands at $2.9 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares decreased by 5.09% to $1.12. The company's market cap stands at $2.9 million. </li>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) shares fell 5.08% to $0.41. The market value of their outstanding shares is at $3.7 million. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) stock decreased by 5.0% to $4.37. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

AKAN

Alterity Therapeutics Limited - American Depositary Shares

ATHE

DOMH

DRMA

IONM

PPBT

SLDB

SNPX

VCNX

12 Health Care Stocks Moving In Friday's After-Market Session

Lantern Pharma shares are trading lower after the company reported worse-than-expected Q1 GAAP EPS results.

Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.43) by 18.6 percent. This is a 41.67 percent decrease over losses of $(0.36) per share from the same period last year.

Earnings Misses

Lantern Pharma Q1 2024 GAAP EPS $(0.51) Misses $(0.43) Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Flanternpharma.com%2F&amp;esheet=53972305&amp;newsitemid=20240506086673&amp;lan=en-US&amp;anchor=Lantern+Pharma+Inc&amp;index=1&amp;md5=b37d304bf4cb42f406c0c3a52d814a49">Lantern Pharma Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Foregon-therapeutics.com%2F&amp;esheet=53972305&amp;newsitemid=20240506086673&amp;lan=en-US&amp;anchor=Oregon+Therapeutics&amp;index=2&amp;md5=74f1a9336f81b8e162166875cef07fc1">Oregon Therapeutics</a>&nbsp;to optimize the development of its first-in-class&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faacrjournals.org%2Fcancerres%2Farticle%2F76%2F14_Supplement%2F3760%2F541311%2FAbstract-3760-XCE853-is-a-promising-protein&amp;esheet=53972305&amp;newsitemid=20240506086673&amp;lan=en-US&amp;anchor=protein+disulfide+isomerase+%28PDI%29&amp;index=3&amp;md5=112b09aa889044031c730365c364d87f">protein disulfide isomerase (PDI)</a>(1)&nbsp;inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its proprietary RADR&reg;&nbsp;AI platform to uncover biomarkers and efficacy-associated signatures of XCE853 across solid tumors that can aid in precision development. Collaborative efforts are expected to identify biomarker signatures that can be used to stratify tumors most responsive to XCE853 and guide potential future clinical development and patient selection. Oregon Therapeutics is developing XCE853 in various cancer indications, including drug-resistant ovarian and pancreatic cancer, certain hematological cancers and several pediatric cancers including CNS cancers.

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) with a Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Lantern Pharma

Lantern Pharmashares  are trading higher after the company was approved to expand its Harmonic clinical trial for non-small cell lung cancer in never-smokers into Japan and Taiwan.

<ul>
<li>never smokers – a growing and unaddressed patient population.</li>
<li>Dr. Yashushi Goto a leading lung cancer clinician-scientist at the renowned National Cancer Center of Japan will be a lead investigator.</li>
</ul>

Lantern Pharma Approved To Expand Harmonic Clinical Trial For Non-Small Cell Lung Cancer In Never-Smokers Into Japan and Taiwan

Shares of Wang &amp; Lee Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) rose sharply in today's pre-market trading after the company reported a year-over-year <a href="https://www.benzinga.com/quote/WLGS/earnings">increase in FY23 financial results</a>.
Wang &amp; Lee Group posted a FY23 loss of 2 cents per share, versus a year-ago loss of 5 cents per share. The company's revenue came in at $6.83 million versus, $4.17 million in the year-ago period, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Wang &amp; Lee Group shares jumped 37.7% to $0.7220 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading" id="h-gainers">Gainers</h3>
<ul>
<li>Redwoods Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWOD#NASDAQ">RWOD</a>) shares gained 141% to $17.83 in pre-market trading after falling around 3% on Thursday.</li>
<li>Zhongchao Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) gained 75.6% to $2.53 in pre-market trading after gaining over 7% on Thursday.</li>
<li>Trio Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NYSE">TPET</a>) gained 30% to $0.4261 in pre-market trading. The company on Wednesday announced it entered into a securities purchase agreement with an institutional investor in the amount of $360,000.</li>
<li>HUB Cyber Security Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBC#NASDAQ">HUBC</a>) shares rose 24.7% to $1.61 in pre-market trading after falling 4% on Thursday.</li>
<li>SuperCom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) gained 22% to $0.2927 in pre-market trading. SuperCom shares fell around 33% on Thursday after the company priced a $2.9 million registered direct offering.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) rose 19.3% to $5.01 in today's pre-market trading after jumping 30% on Thursday. Bio-Path announced a $1.2 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Centogene N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTG#NASDAQ">CNTG</a>) shares gained 19.3% to $0.5513 in pre-market trading.</li>
<li>Kineta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) rose 14.7% to $0.5601 in pre-market trading. Kineta was recently granted a US patent titled &#8216;Proteasome activity enhancing compounds (including methods for treating cancer or tumors).&#8217;</li>
<li>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) shares gained 10.5% to $12.12 in pre-market trading. Apollo Global Management and Sony Group Corp. are reportedly in talks on a joint offer for Paramount Global.</li>
</ul>
<h3 class="wp-block-heading" id="h-losers">Losers</h3>
<ul>
<li>BioNexus Gene Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) fell 22.4% to $0.66 in pre-market trading after jumping around 29% on Thursday. BioNexus Gene Lab agreed to invest RM 1.2 million in Ascension Innovation (AISB) to advance digital health innovation through AI adoption in healthcare.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) fell 19.9% to $0.6407 in pre-market trading after surging 65% on Thursday.</li>
<li>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) fell 19.3% to $0.3396 in pre-market trading after gaining around 98% on Thursday.</li>
<li>AGBA Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGBA#NASDAQ">AGBA</a>) fell 13.6% to $0.89 in pre-market trading. AGBA Group Holding shares jumped 155% on Thursday higher after the company announced it entered into a definitive merger agreement with Triller.</li>
<li>Spectaire Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPEC#NASDAQ">SPEC</a>) declined 12.3% to $0.5426 in pre-market trading after falling over 20% on Thursday. Spectaire Holdings recently signed a distribution partnership agreement with a Fortune 1000 Energy Company.</li>
<li>Lantern Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) shares fell 12.1% to $5.07 in pre-market trading.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares declined 11.4% to $2.07 in pre-market trading. Adaptive Biotechnologies is expected to report financial results for the first quarter 2024 after the closing bell on May 7, 2024.</li>
<li>Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares fell 11.1% to $0.3870 in pre-market trading. Soligenix shares fell around 15% on Thursday after the company announced the pricing of a $4.75 million public offering.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) fell 10.2% to $2.65 pre-market trading after jumping around 32% on Thursday.</li>
<li>Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) fell 6% to $573.81 pre-market trading. Netflix reported upbeat earnings and sales results for its first quarter. The company added 9.33 million paid net new subscribers in the first quarter to bring the company to a total of 269.60 million.</li>
</ul>

Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38329059/netflix-procter-gamble-and-3-stocks-to-watch-heading-into-friday">Netflix, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Friday</a>

Pre-Market Outlook

Markets

ADPT

AGBA

BGLC

BPTH

CNTG

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HUBC

ISPC

NFLX

PARA

RWOD

SNGX

SPCB

SPEC

TIRX

TPET

WLGS

ZCMD

Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

Lantern Pharma GAAP EPS of -$0.51 misses by $0.08

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Lantern Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/ltrn-stock-quote/">LTRN</a>) just reported results for the first quarter of 2024.<ul><li>Lantern Pharma reported earnings per share of -51 cents. This was below the analyst estimate for EPS of -43 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ltrn-stock-earnings-lantern-pharma-for-q1-of-2024/">LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024

Analysts have been eager to weigh in on the Healthcare sector with new ratings on ALX Oncology Holdings (ALXO – Research Report), Lantern Pharma (L...

Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Lantern Pharma (LTRN) and OmniAb (OABI)

Lantern Pharma files for $150M mixed shelf offering

Lantern Pharma announces update from mid-stage trial for non-small cell lung cancer treatment

Lantern Pharma (LTRN) has issued an announcement. On August 8, 2024, the Company is set to host a conference call and live webinar to discuss its s...

Lantern Pharma Q2 Results and LP-300 Clinical Trial Update

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Lantern Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/ltrn-stock-quote/">LTRN</a>) just reported results for the second quarter of 2024.<ul><li>Lantern Pharma reported earnings per share of -46 cents. This was above the analyst estimate for EPS of -55 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ltrn-stock-earnings-lantern-pharma-for-q2-of-2024/">LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024

Lantern Pharma GAAP EPS of -$0.46 beats by $0.09

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Lantern Pharma Inc. 2024 Q2 - Results - Earnings Call Presentation

ALXO

OABI

Press Releases

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Lantern Pharma to Host & Participate in Two Public Webinars During October

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Comments

Lantern Pharma

Notizie

Ultime notizie per Lantern Pharma (NASDAQ:LTRN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO